Effect and mechanism of lipopolysaccharide on allergen-induced interleukin-5 and eotaxins production by whole blood cultures of atopic asthmatics

J.-W. Min,*[‡] S.-M. Park,*[‡] T. Y. Rhim,* S.-W. Park,* A.-S. Jang,* S.-T. Uh,* C.-S. Park*[‡] and I. Y. Chung[†] *Genome Research Center for Allergy and Respiratory Diseases, Division of Allergy and Respiratory Medicine, Soonchunhyang University Bucheon Hospital, Korea, and [†]Division of Molecular and Life Science, Hanyang University, Korea

Accepted for publication 21 November 2006 Correspondence: Dr Choon-Sik Park, Division of Allergy and Respiratory Medicine, Soonchunhyang University Bucheon Hospital, 1174, Jung Dong, Wonmi Ku, Bucheon, Gyeonggi Do, 420–021, Republic of Korea. E-mail: mdcspark@unitel.co.kr

^{*}Ji-Won Min and Se-Min Park equally contributed to this work.

Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.

Summary

Interleukin (IL)-5 and eotaxin families regulate the development of eosinophilic inflammation of asthma in a co-operative manner. The exposure to airborne lipopolysaccharide (LPS) induces varying degrees of airflow obstruction and neutrophilic airway inflammation. Production of IL-5 and eotaxin subfamily chemokines was analysed in response to Dermatophagoides pteronyssinus allergen (D.p.) according to the presence of specific IgE to D.p., and investigated the mechanism underlying their LPS-mediated regulation of these cytokines in response to the specific allergen. Peripheral blood cells (PBCs) from asthmatics with (group 1) or without (group 2) specific IgE to D.p. and from non-asthmatics with (group 3) or without (group 4) were stimulated with D.p. or LPS. For LPS-mediated inhibition of IL-5 and eotaxin-2 production, LPS-induced cytokines were added to the D.p.stimulated PBCs. IL-5 and eotaxin-2, but not eotaxin-1 and 3, were significantly increased by D.p.-stimulated-PBCs from group 1, while only eotaxin-2 was elevated in group 3. Eotaxin-2 production was found in monocytes and correlated with the level of specific IgE to D.p. LPS treatment resulted in the decrease in eotaxin-2 and IL-5 production by the D.p.-stimulated PBCs. LPSinduced IL-10 completely inhibited D.p.-stimulated production of eotaxin-2 and IL-5. The differential responses of the eotaxin family to specific antigens suggest that the predominant role of eotaxin-2 and LPS may attenuate eosinophilic inflammation by inhibiting IL-5 and eotaxin-2 synthesis through IL-10 production.

Keywords: asthma, D.p. antigen, eotaxin-2, interleukin-10, interleukin-5, LPS

OnlineOpen: This article is available free online at www.blackwell-synergy.com

Introduction

Allergic asthma has been regarded as an atopic disease involving allergen exposure, allergic (IgE-mediated) sensitization with a Th2 CD4⁺ lymphocyte response and subsequent interleukin (IL)-5-mediated eosinophilic airways inflammation, resulting in enhanced bronchial reactivity and reversible airflow obstruction [1]. In this process, antigen-sensitized T helper 2 (Th2) cells play a key role in development of the manifestations through their production and release of specific cytokines, such as IL-4, IL-5 and IL-13 [2]. The eotaxin subfamily, a member of CC chemokines, also participates in the development of asthma and other allergic disorders through the mobilization of inflammatory cells bearing CCR3, especially eosinophils. The potent effects of eotaxins on eosinophils in concert with IL-5 are explained largely by their ability to signal through the CCR3 [3]. Three members of this family have been identified: eotaxin-1 [4], eotaxin-2 [5] and eotaxin-3 [6], and the three eotaxins share the same CCR3 [7,8]. While limited studies have demonstrated their differential expression and their roles in regulating the kinetics of eosinophil recruitment during allergic inflammation [9–12], the eotaxins/CCR3 pathway evidently plays a fundamental role in eosinophil recruitment in experimental allergic asthma [10,13]. In allergen-sensitized atopic asthmatic subjects, *in vitro* allergen stimulation induces IL-5 production by peripheral blood mononuclear cells (PBMC) [14]; however, it has not been evaluated whether the synthesis of eotaxins depends on antigen sensitization.

The exposure to airborne lipopolysaccharide (LPS) induces varying degrees of airflow obstruction and neutrophil inflammation and is often associated with an exacerbation of established asthma in children and adults [15,16]. However, emerging evidence suggests that exposure to endotoxin in early life prevents the development of atopy and, potentially, allergic asthma [17-19]. The inhibitory effect of LPS is mediated presumably by the induction of Th1 cytokines such as interferon (IFN)-ã and IL-12 secretion [18,20,21] or regulatory cytokines such as IL-10 [22]. However, the effect and mechanisms of LPS on antigensensitized IL-5 and eotaxins production has not yet been evaluated. In this study, we employed an ex vivo stimulation of peripheral whole blood cells (PBCs) that were obtained from four groups of asthmatics and non-asthmatics with or without specific IgE to mite Dermatophagoides pteronyssinus (D.p.). The production of cytokines and eotaxin subfamily chemokines in response to the mite antigen and the mechanism(s) underlying their LPS-mediated regulation were analysed.

Methods

Subjects

The study subjects comprised four groups: asthmatics with (group 1) or without (group 2) D.p.-specific IgE, normal controls with (group 3) or without (group 4). The asthmatics had clinical symptoms and physical characteristics compatible with the Global Initiative for Asthma (GINA) guidelines [23]. Asthmatics showed airway reversibility, as documented by an inhalant bronchodilator-induced improvement of more than 15% of forced expiratory volume in 1 second (FEV1) and/or an airway hyperresponsiveness (AHR) to <10 mg methacholine/ml [24]. Allergy skin prick tests were performed using 24 commercial inhalant allergens, which included dust mites (Dermatophagoides farinae and D. pteronyssinus, Bencard, West Sussex, UK) and histamine (1 mg/ml). IgE specific to D.p. was measured using the CAP system (Pharmacia Diagnostics, Uppsala, Sweden) and was presented as specific IgE class (1-6) according to UniCap-specific IgE Unites (kU_A/l). All subjects gave informed consent to participate in the study, and the protocols were approved by the local ethics committee of Soonchunhyang University Hospital.

Cell culture and cytokine/chemokine production

Peripheral blood was diluted at a 1:1 ratio with tissue culture medium containing RPMI-1640, 2 mM L-glutamine, 25 mM HEPES, 100 U penicillin/ml and 100 µg streptomycin/ml (JBI, Daegu, Korea). PBCs were stimulated with various concentrations of D.p., which was generously gifted by Professor Hong [25], and LPS (*Escherichia coli* 0111:B4, L-2630) (Sigma, St. Louis, MO, USA) for different

lengths of time. The culture supernatants were harvested by centrifugation and were stored at -20° C until assayed. The potency of the D.p. was measured by specific IgE inhibition test with the pooled sera of 10 asthmatics having specific IgE (score > 4), as described previously [26]. Fifty per cent inhibition was obtained by preincubation of the pooled serum with 10 µg D.p. extract/ml. The endotoxin concentration of the mixture containing 10 µg D.p./ml was < 0.283 EU/ml (equivalent to 28.3 pg/ml), as determined by a limulus amoebocyte lysate kit (Bio-Whittaker, Walkersville, MD, USA).

Measurement of cytokine and chemokine concentrations

Cytokine and eotaxin concentrations were determined by enzyme-linked immunosorbent assay (ELISA), using kits from R&D Systems (Minneapolis, MN, USA) for eotaxin-2, and eotaxin-3 and kits from BD Biosciences (San Diego, CA, USA) for eotaxin-1, IL-5, IFN- γ , IL-12 and IL-10. The detection limits for eotaxin-1, eotaxin-2, eotaxin-3, IL-5, IFN- γ , IL-12 and IL-10 were 6·3, 15·6, 62·5, 3·9, 18·7, 31·3 and 15·6 pg/ml, respectively. All concentrations below these limits were considered as the detection limit values above for the statistical analysis. The inter- and intra-assay coefficients of variance were below 10%.

Immunocytochemical detection of intracellular eotaxin-2

Peripheral blood leucocytes were isolated from the venous blood of D.p.-specific IgE-positive asthmatics using a Percoll gradient solution. A total of 1×10^7 cells were cultured for 72 h in the presence of autologous serum (10% v/v) and 10 µg D.p./ml, with 3 µM monensin (Sigma, M5273) added 6 h before the termination of culture. The cultured cells were cytocentrifuged and fixed with 1% paraformaldehyde and 0.1% saponin. Eotaxin-2-positive cells were identified by immunostaining with anti-human eotaxin-2 (R&D Systems) and biotinylated goat-anti-mouse IgG (Vector Laboratories, Burlingame, CA, USA). The negative control was incubated with isotype-matched antibody. The cells were then counterstained with Wright–Giemsa.

Inhibition and blocking of cytokine production in PBCs stimulated with D.p.

For inhibition studies, various concentrations of IL-10, IL-12 (R&D Systems) and IFN- γ (BD Bioscience) were added to PBCs in the presence of D.p. (10 µg/ml). For blocking, PBCs were pretreated for 30 min with various concentrations of mouse anti-human IL-10R α antibody (R&D Systems) or mouse anti-human TLR4 antibody (BD Bioscience) and then for 72 h with D.p. (10 µg/ml) or LPS (10 ng/ml).

Table 1. Clinical profiles of the study subjects.

	Asthma		Normal control	
	Group 1	Group 2	Group 3	Group 4
Subject (M/F)	20 (10/10)	12 (7/5)	7 (5/2)	10 (4/6)
Age (years)	30.9 ± 2.6	33.83 ± 1.2	29.71 ± 2.4	32.0 ± 3.6
Current smoker (%)	38	33.3	32.5	30
FEV1%, predicted	$81.1 \pm 2.2^{\dagger}_{2}$	97.2 ± 4.8	101.7 ± 4.2	107.8 ± 6.3
Methacholine PC ₂₀ (mg/ml)	$2.1 \pm 1.4^{+1}$	2.7 ± 1.1 §¶	> 25	> 25
Blood eosinophil (%)	$5.1 \pm 0.7^{+1}$	6.2 ± 1.59	2.1 ± 0.2	1.7 ± 0.4
Skin test to D.p. (%)	100*‡	0 ^{££}	100**	0
Total IgE (U/ml)	571·5 ± 127·6*‡¶	203.9 ± 76.49	$185.1 \pm 37.6^{**}$	22.8 ± 6.2
Specific IgE, to D.p. antigen	$3.7 \pm 0.2^{*}^{\dagger}_{\dagger}^{\ddagger}$	0 ± 0 §	$2.7 \pm 0.3^{**}$	0 ± 0

Specific IgE is presented as specific IgE class (grades 1–6) according to Unicap-specific IgE Unites (kU_A/l). Values are the means \pm s.e.m. *P*-values were obtained using the Mann–Whitney *U*-test or the χ^2 test. The following symbols represent significant differences (P < 0.05) between two groups: *between groups 1 and 2, †between groups 1 and 3, ‡between groups 1 and 4, §between groups 2 and 3, ¶between groups 2 and 4 and **between groups 3 and 4.

Reverse transcriptase–polymerase chain reaction (RT–PCR)

PBCs from group 1 were stimulated for 72 h with D.p. in the presence or absence of LPS and/or various concentrations of anti-IL-10Ra. PBMCs were then isolated from the cultured PBCs. Total RNA was extracted and reverse-transcribed by incubation with 200 U SuperScript RT (Invitrogen Life Technologies, Grand Island, NY, USA) at 42°C for 50 min. The resulting cDNA were placed into tubes containing specific primer pairs for human eotaxin-2, IL-5 or glyceraldehyde-3phosphate-dehydrogenase (GAPDH) gene, and were amplified for 30 cycles (one cycle: 1 min at 95°C, 1 min at 55°C and 1 min at 72°C). The PCR products were resolved by agarose (1%) gel electrophoresis. The primers used were follows; eotaxin-2 forward primer 5'-GCTCTGTGGTCATCCCCTC TCCCTG-3', reverse primer 5'-GCAGGTGGTTT GGTTC CAGGATAT-3'; IL-5 forward primer 5'-GAG GATGCTTC TGCATTTGAGTTTG-3', reverse primer 5'-GTCAATGT ATTTCTTTATTAAGGACAAG-3'; GAPDH forward primer 5'-GGCATTGCTCTC AATGACAA-3', reverse primer 5'-AGGGCCTC TCT CTTGCTCTC-3'.

Statistical analysis

Data were expressed as mean \pm s.e.m. Statistical analysis was carried out using the spss program (version 11.0; SPSS Inc., Chicago, IL, USA). Differences between independent groups or samples were compared using the nonparametric Kruskal–Wallis *H*-test for continuous data. If differences were found to be significant, the Mann–Whitney *U*-test was applied to compare differences between two samples. The Wilcoxon signed rank test was applied for time-dependent changes in the parameters. Spearman's rank correlation was calculated to assess correlations between data.

Results

Subject details

Asthmatics (groups 1 and 2) had significantly lower FEV_1 and methacholine PC_{20} values than did non-asthmatics (groups 3 and 4), while the former exhibited higher blood eosinophil levels than the latter. Specific and total IgE were significantly higher in the subjects allergic to D.p. (groups 1 and 3) than in the non-allergic groups (groups 2 and 4) (Table 1). These findings are consistent with previously described criteria [27].

Production of cytokines and chemokines by PBCs in response to D.p.

Throughout this study, a bulk whole blood culture system was employed in which peripheral blood was diluted at a 1:1 ratio with culture medium and used without fractionation. To optimize IL-5 and eotaxin subfamilies production, PBCs from group 1 (n = 7) were stimulated with various doses of D.p. for different periods of time. Eotaxin-2 and IL-5 increased continuously until 120 h after stimulation with a dose of 10 µg/ml D.p. and was elevated significantly compared with those of unstimulated PBC, whereas eotaxin-1 was decreased. No significant differences were found in eotaxin-3 production. Increased IL-5 and eotaxin-2 production by PBCs for 72-h stimulation with D.p. antigen reached a plateau at a dose of 10 µg/ml D.p and eotaxin-1 was significantly down-regulated upon exposure of PBCs in a dose-dependent manner to D.p. antigen (Fig. 1a).

Next, we stimulated PBCs from subjects of four groups. To minimize the effect derived from both different absolute and relative numbers of leucocytes in each group and in each individual within the group, the results were expressed as a fold increase of D.p. stimulation *versus* D.p. non-stimulation. PBCs were obtained from four groups (group 1, n = 20;





Fig. 1. (a) Time kinetics and dose–responses of IL-5 and eotaxin family chemokine production by D.p.-stimulated PBCs. PBCs were prepared from group 1 (n = 7) and were stimulated with various concentrations of D.p. for different lengths of time. Data are expressed as the means ± SEM. The statistical analysis was carried out using the Wilcoxon signed rank test. *P < 0.05, **P < 0.01. (b) Production of IL-5 and eotaxin subfamilies by D.p.-stimulated PBCs. PBCs were stimulated with either medium or 10 µg D.p./ml for 72 h. Groups 1, 2, 3, and 4 included 20, 12, 7, and 10 individual samples, respectively. The amounts of cytokines were expressed as a fold increase in which cytokine levels in the presence of D.p. were divided by those in its absence. *P < 0.05, **P < 0.01 vs. cytokine levels in the absence of D.p. (c) Inhibition of D.p.-induced production of eotaxin-2 and IL-5 by LPS. PBCs from group 1 (n = 7) were treated with increasing concentrations of LPS in the presence of D.p. (10 µg/ml) for 72 h, and the eotaxin-2 and IL-5 levels in the culture supernatants were determined. *P < 0.05, **P < 0.01 vs. D.p.-induced production of eotaxin-2 and IL-5. Cytokine production was determined by ELISA. (d) Percoll gradient-isolated leukocytes from group 1 were stimulated with medium (panels 1, 2) or D.p. antigen (panels 3, 4), cytospin, and either incubated with anti-human eotaxin-2 antibody (panels 1, 3) or stained with Wright-Giemsa solution (panels 2, 4). Bar =10 µm.



Fig. 2. Correlation of eotaxin-2 production with plasma IgE specific to D.p. and with production of eotaxin-2. Eotaxin-2 production in D.p.-stimulated PBCs from asthmatics positive to D.p. (group 1, n = 20; group 3, n = 7) was plotted against the level of plasma IgE specific to it. The statistical analysis was carried out using Spearman's rank test.

group 2, n = 12; group 3, n = 7; and group 4, n = 10) and were stimulated with D.p. (10 µg/ml) for 72 h. The significantly increased production of IL-5 was observed only in group 1, while eotaxin-2 was elevated in groups 1 and 3 (Fig. 1b). In contrast, eotaxin-1 production decreased significantly in groups 1 and 3. Eotaxin-3 was not changed in the four groups (Fig. 1b). Eotaxin-2 production in groups 1 and 3 correlated strongly with the respective levels of specific

serum IgE to D.p. (r = 0.528, P = 0.017 for group 1 and r = 0.810, P = 0.027 for group 3) (Fig. 2). Immunocytochemical and Wright–Giemsa staining of PBCs from group 1 showed that monocytes were the eotaxin-2producing cells (Fig. 1d).

Inhibitory effect of LPS on D.p.-induced eotaxin-2 and IL-5 production

As eotaxin-2 and IL-5 levels increased following stimulation with D.p., the production of these two cytokines in response to LPS was examined. PBCs from group 1 (n = 7) were stimulated with increasing concentrations of LPS in the presence of D.p. (10 µg/ml). The results showed that eotaxin-2 and IL-5 production declined in a dose-dependent fashion. Eotaxin-2 was inhibited completely (P = 0.01) and IL-5 was inhibited by 80% (P = 0.01) at 10 ng/ml LPS (Fig. 1c). To examine whether the inhibitory effect of LPS was mediated through Toll-like receptor 4 (TLR4), a neutralization antibody to TLR4 was added to PBC cultures from group 1 (n = 6) in the presence of D.p. (10 µg/ml) and LPS (10 ng/ml). Eotaxin-2 and IL-5 production were partly restored by neutralization with anti-TLR4 in a dose-dependent manner (Fig. 3a), suggesting an inhibitory mechanism via TLR4. To identify which factor(s) mediate the inhibitory effect of LPS on the D.p.induced production of eotaxin-2 and IL-5, production of



Fig. 3. (a) The effect of anti-TLR4 on LPS-induced inhibition of eotaxin-2 and IL-5 production. PBCs were prepared from group 1 (n = 6) and were incubated with different concentrations of anti-TLR4 in the presence of LPS (10 ng/ml) and D.p. antigen (10 µg/ml) for 72 h. (b) IFN- γ , IL-12, and IL-10 production by PBCs stimulated with LPS. Group 1 PBCs (n = 7) were stimulated with LPS (0.1–100 ng/ml) for 72 h. The amounts of cytokine were measured by ELISA. Data are expressed as the means ± SEM. The statistical analysis was carried out using the Wilcoxon signed rank test. *P < 0.05, **P < 0.01.



Fig. 4. The inhibitory effects of IL-10 on D.p. antigen-stimulated production of eotaxin-2 and IL-5. PBCs were prepared from group 1 (n = 8). (a) PBCs were stimulated with D.p. (10 µg/ml) for 72 h in the absence or presence of recombinant IL-10, IFN- γ , or IL-12 (each 0.01–1 ng/ml). (b) PBCs were stimulated with D.p. (10 µg/ml) and LPS (10 ng/ml) in the presence of increasing concentrations of anti-IL-10R α (0.01–1 µg/ml) for 72 h, and eotaxin-2 and IL-5 production was evaluated. The statistical analysis was carried out using the Wilcoxon signed rank test. *P < 0.05, **P < 0.01. (c) PBMCs from group 1 (n = 8) and were stimulated under the indicated conditions for 72 h.

cytokines (IL-5, IFN- γ , IL-12 and IL-10) and eotaxins was analysed in group 1 PBCs (n = 7) stimulated with LPS alone. Among these, IFN- γ , IL-12 and IL-10 were significantly up-regulated upon the exposure of PBCs in a dose-dependent manner of LPS (Fig. 3b).

LPS inhibits D.p.-induced production of IL-5 and eotaxin-2 via IL-10 production

The three cytokines induced by LPS were examined individually for their inhibitory effect on the production of eotaxin-2 and IL-5 by D.p.-stimulated PBCs from group 1 (n = 8). IL-10 inhibited eotaxin-2 and IL-5 production almost completely (Fig. 4a). In contrast, IFN- γ significantly augmented the production of both cytokines, and IL-12 had no effect. Anti-IL-10R α suppressed dose-dependently the inhibitory effect of LPS on D.p.-stimulated IL-5 production but not eotaxin-2 production (Fig. 4b), suggesting that a signal transmitted through the IL-10R effectively blocks IL-5 production by D.p.-primed Th2 cells, yet is not effective for monocyte eotaxin-2 production. RT–PCR analysis showed

that the LPS-mediated inhibition as well as the restoration of IL-5 mRNA expression by anti-IL-10R α indeed occurred at the transcriptional level (Fig. 4c). The neutralization of eotaxin-2 mRNA expression by anti-IL-10R α was not observed, indicating that the inhibitory effects of LPS on D.p.-induced IL-5 and eotaxin-2 production are regulated differently.

Discussion

We employed an *ex vivo* stimulation of peripheral blood cells (PBCs) that were obtained from four groups of asthmatics and non-asthmatics with or without specific IgE to mite D.p. PBC contains lymphocytes, monocytes and other leucocytes. It also contains an array of protein and non-protein factors that may influence the availability of the antigen and LPS used. Thus it functionally represents the *in vivo* milieu more accurately than do purified peripheral blood leucocytes or combinations thereof.

Stimulation of PBCs with D.p. resulted in characteristic expression patterns of IL-5 and eotaxin subfamily

chemokines. We identified increased IL-5 and eotaxin-2 production in D.p.-stimulated PBCs from the specific IgEpositive (group 1) and monocytes as a major producer of eotaxin-2. This result indicates the strict dependence of IL-5 and eotaxin-2 production on sensitization with specific antigens. IL-5 synthesis was observed only in PBCs from group 1. This result is in agreement with a previous study in which allergen-induced IL-5 production by PBMC from sensitized atopic subjects with symptoms, but not subjects without symptoms, is elevated [14].

CD23, a low-affinity receptor of IgE (FcåRII), is expressed at a much higher level in monocytes from allergic asthmatics than in cells from normal individuals [28]. It is therefore speculated that D.p. may form a complex with circulating specific IgE to induce eotaxin-2 production through the engagement of abundant CD23 on monocytes from allergic subjects. As a result, eotaxin-2 production may be related to the presence of specific IgE. Our data demonstrate that eotaxin-1 is down-regulated and eotaxin-2 is up-regulated by D.p., while eotaxin-3 remains unchanged. This may be due to different cell sources of each eotaxin. While monocytes are a major source of eotaxin-2, eotaxin-1 and 3 are produced mainly by epithelial cells [9]. Limited studies have demonstrated the differential expression and roles of eotaxin subfamilies in regulating the kinetics of eosinophil recruitment during allergic inflammation [11,29]. However, experimental asthma models using eotaxin 1 and/or eotaxin 2 knock-out mice showed a dominant role of eotaxin-2 in ovalbumin (OVA)-induced airway eosinophilia [13], in spite of a co-operative role for eotaxin-1 and eotaxin-2 in recruitment of eosinophils to the lung tissue. We have shown that polymorphism in the gene encoding eotaxin-2, but not eotaxin-1, is associated with a risk of asthma [30] and correlates with plasma eotaxin-2 levels [31]. These data, including ours, may suggest a dominant role of eotaxin-2 among the eotaxin subfamily in peripheral circulation of atopic asthma.

The effect of endotoxin exposure in asthma is still controversial. The beneficial effects of LPS are thought to be mediated by enhanced secretion of IFN-y and IL-12 [32,33], whereas LPS affects asthmatics adversely by enhancing established airway inflammation and airway obstruction [16]. In the present study, we showed that LPS inhibited dosedependently the production of IL-5 and eotaxin-2 in response to specific antigen; thus only IL-10 almost completely inhibited antigen-induced production of IL-5 and eotaxin-2 (Figs 1-3). The other novel finding of our study is that blocking the functioning receptor of IL-10 (IL-10R α) restored the inhibitory effect of LPS only on IL-5 production (Fig. 4). These data suggest that the effect of LPS against the manifestation of allergic asthma is achieved by reducing eosinophilic inflammation through the up-regulation of IL-10 production. In support of this finding, IL-10 has been shown to exhibit anti-allergic activity in sensitized mice by preventing IL-5 release and antigen-induced CD4⁺ T lymphocyte and eosinophil accumulation [22].

Systemic administration of endotoxin to healthy subjects produced a selective induction of Th1, as confirmed by increased IL-2 production versus decreased IFN-gamma production and Th2 chemokine ligands such as CCR4 receptor [34]. These in vivo data were not in agreement with ours in terms of different patterns of IFN-gamma production. It would be interesting to evaluate whether IL-10 production is elevated in a human endotoxin model, but this has not yet been attempted. In contrast to systemic administration, inhalation of endotoxin induced different patterns of reaction in the airways. Inhalation of endotoxin has been recognized as an important factor in the aetiology of occupational lung diseases, including non-allergic asthma [35]. Eosinophilic inflammation is generally considered to be the main feature of allergic asthmatic airways and is presumed to be crucial in the pathogenesis of allergic asthma [36]. Endotoxin in house dust is associated with exacerbations of preexisting asthma in children and adults [16,37], and induces neutrophilic airways inflammation via IL-8 secretion [38]. The switching of eosinophilic inflammation into neutrophilic inflammation in the acute exacerbation of allergic asthma is contributed mainly by up-regulation of neutrophilic chemokines such as IL-8. In addition, downregulation of IL-5 and eotaxin may be one mechanism to reduce the eosinophilic inflammation in the LPS-induced neutrophilic airway inflammation of asthmatics, as shown in experimental models [39], although this has not been revealed in the airways of asthmatics. IL-10 may exert an inhibitory effect on eotaxin-2 production via another pathway such as IL-10R β [40], or an unknown pathway. Intriguingly, IFN- γ treatment enhanced the production of IL-5 and eotaxin-2 by antigen-stimulated PBCs, while IL-12 had no effect (Fig. 4a). This observation is in line with previous findings that the suppression of airway eosinophilia and AHR by LPS [41] or killed mycobacteria [42] is not attributable to a Th1 shift.

In summary, two important conclusions can be drawn from our results: first, specific antigen-stimulated wholeblood cultures from asthmatics and normal controls with or without specific IgE to D.p. produce unique patterns of IL-5 and eotaxin-2. Secondly, LPS inhibits antigen-induced production of IL-5 and eotaxin-2 via IL-10 secretion. The inhibitory effect of endotoxin may be associated with its ability to attenuate eosinophilic inflammation or eosinophilmediated immune responses.

Acknowledgements

This work was supported by a grant from Korea Research Foundation (KRF-2003–041-E00123).

References

- 1 Cambell P, Weiss U. Allergy and asthma. Nature 1999; 402:B1-38.
- 2 Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999; 54:825-7.

- 3 Rothenberg ME, Hogan SP. Overview. In: Rothenberg ME, ed. Chemokines in allergic disease. New York: Marcel Dekker, Inc., 2000:1–15.
- 4 Garcia-Zepeda EA, Rothenberg ME, Weremowicz S, Sarafi MN, Morton CC, Luster AD. Genomic organization, complete sequence, and chromosomal location of the gene for human eotaxin (SCYA11), an eosinophil-specific CC chemokine. Genomics 1997; 41:471–6.
- 5 Nomiyama H, Osborne LR, Imai T *et al.* Assignment of the human CC chemokine MPIF-2/eotaxin-2 (SCYA24) to chromosome 7q11.
 23. Genomics 1998; 49:339–40.
- 6 Guo RF, Ward PA, Hu SM, McDuffie JE, Huber-Lang M, Shi MM. Molecular cloning and characterization of a novel human CC chemokine, SCYA26. Genomics 1999; 58:313–7.
- 7 White JR, Imburgia C, Dul E *et al.* Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils. J Leukoc Biol 1997; 62:667–75.
- 8 Patel VP, Kreider BL, Li Y *et al.* Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors. J Exp Med 1997; 185:1163–72.
- 9 Komiya A, Nagase H, Yamada H *et al.* Concerted expression of eotaxin-1, eotaxin-2, and eotaxin-3 in human bronchial epithelial cells. Cell Immunol 2003; **225**:91–100.
- 10 Yang M, Hogan SP, Mahalingam S et al. Eotaxin-2 and IL-5 cooperate in the lung to regulate IL-13 production and airway eosinophilia and hyperreactivity. J Allergy Clin Immunol 2003; 112:935–43.
- Berkman N, Ohnona S. Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. Am J Respir Cell Mol Biol 2001; 24:682–7.
- 12 Ravensberg AJ, Ricciardolo FL, zan Schadewijk A *et al.* Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge. J Allergy Clin Immunol 2005; **115**:779–85.
- 13 Pope SM, Zimmermann N, Stringer KF, Karow ML, Rothenberg ME. The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia. J Immunol 2005; 175:5341–50.
- 14 Till S, Dickason R, Huston D *et al.* IL-5 secretion by allergenstimulated CD4+ T cells in primary culture: relationship to expression of allergic disease. J Allergy Clin Immunol 1997; 99:563–9.
- 15 Michel O, Ginanni R, Le Bon B, Content J, Duchateau J, Sergysels R. Inflammatory response to acute inhalation of endotoxin in asthmatic patients. Am Rev Respir Dis 1992; 146:352–7.
- 16 Michel O, Kips J, Duchateau J *et al.* Severity of asthma is related to endotoxin in house dust. Am J Respir Crit Care Med 1996; 154:1641–6.
- 17 Eldridge MW, Peden DB. Allergen provocation augments endotoxin-induced nasal inflammation in subjects with atopic asthma. J Allergy Clin Immunol 2000; 105:475–81.
- 18 Gereda JE, Leung DY, Thatayatikom A *et al.* Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitization in infants at high risk of asthma. Lancet 2000; 355:1680–3.
- 19 Holt PG, Sly PD. Prevention of adult asthma by early intervention during childhood: potential value of new generation immunomodulatory drugs. Thorax 2000; 55:700–3.

- 20 Tulic MK, Wale JL, Holt PG, Sly PD. Modification of the inflammatory response to allergen challenge after exposure to bacterial lipopolysaccharide. Am J Respir Cell Mol Biol 2000; 22:604–12.
- 21 Morris SC, Madden KB, Adamovicz JJ *et al.* Effects of IL-12 on *in vivo* cytokine gene expression and Ig isotype selection. J Immunol 1994; **152**:1047–56.
- 22 Zuany-Amorim C, Creminon C, Nevers MC, Nahori MA, Vargaftig BB, Pretolani M. Modulation by IL-10 of antigeninduced IL-5 generation, and CD4+ T lymphocyte and eosinophil infiltration into the mouse peritoneal cavity. J Immunol 1996; **157**:377–84.
- 23 Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NHLBI/WHO workshop report, Bethesda, MD National Institutes of Health National Heart, Lung, and Blood Institute; 2002. NIH publication no. 02–3659. J Allergy Clin Immunol 2002; 110:S141–219.
- 24 American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136:225–44.
- 25 Nahm DH, Park JW, Hong CS. Effects of autologous sera on immediate and late skin reaction to the house dust mite in atopic individuals. Yonsei Med J 1995; 36:137–45.
- 26 Gleich GJ, Jones RT. Measurement of IgE antibodies by the radioallergosorbent test. I. Technical considerations in the performance of the test. J Allergy Clin Immunol 1975; 55:334–45.
- 27 Humbert M, Menz G, Ying S *et al.* The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today 1999; 20:528– 33.
- 28 Williams J, Johnson S, Mascali JJ, Smith H, Rosenwasser LJ, Borish L. Regulation of low affinity IgE receptor (CD23) expression on mononuclear phagocytes in normal and asthmatic subjects. J Immunol 1992; 149:2823–9.
- 29 Ying S, Meng Q, Zeibecoglou K *et al.* Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4, and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1999; **163**:6321–9.
- 30 Shin HD, Kim LH, Park BL *et al*. Association of eotaxin gene family with asthma and serum total IgE. Hum Mol Genet 2003; **312**:1279– 85.
- 31 Min JW, Lee JH, Park CS *et al.* Association of eotaxin-2 gene polymorphisms with plasma eotaxin-2 concentration. J Hum Genet 2005; **50**:118–23.
- 32 Iwamoto I, Nakajima H, Endo H, Yoshida S. Interferon gamma regulates antigen-induced eosinophil recruitment into the mouse airways by inhibiting the infiltration of CD4+ T cells. J Exp Med 1993; **177**:573–6.
- 33 Kips JC, Brusselle GJ, Joos GF *et al.* Interleukin-12 inhibits antigeninduced airway hyperresponsiveness in mice. Am J Respir Crit Care Med 1996; **153**:535–9.
- 34 De AK, Miller-Graziano CL, Calvano SE *et al.* Selective activation of peripheral blood T cell subsets by endotoxin infusion in healthy human subjects corresponds to differential chemokine activation. J Immunol 2005; **175**:6155–62.
- 35 Schenker MB, Christiani D, Cormier Y. Respiratory health hazards in agriculture. Am J Respir Crit Care Med 1998; **158**:S1–76.
- 36 Holt PG, Macaubas C, Stumbles PA, Sly PD. The role of allergy in the development of asthma. Nature 1999; **402**:B12–7.

- 37 Rizzo MC, Naspitz CK, Fernandez-Cladas E, Lockey RF, Mimica I, Sole D. Endotoxin exposure and symptoms in asthmatic children. Pediatr Allergy Immunol 1997; 8:121–6.
- 38 Nightingale JA, Rogers DF, Hart LA, Kharitonov SA, Chung KF, Barnes PJ. Effect of inhaled endotoxin on induced sputum in normal, atopic, and atopic asthmatic subjects. Thorax 1998; 53:563–71.
- 39 Cheng SS, Lukacs NW, Kunkel SL. Eotaxin/CCL11 is a negative regulator of neutrophil recruitment in a murine model of endotoxemia. Exp Mol Pathol 2002; 73:1–8.
- 40 Spencer SD, Di Marco F, Hooley J *et al.* The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med 1998; **187**:571–8.
- 41 Rodriguez D, Keller AC, Faquim-Mauro EL et al. Bacterial lipopolysaccharide signaling through Toll-like receptor 4 suppresses asthma-like responses via nitric oxide synthase 2 activity. J Immunol 2003; 171:1001–8.
- 42 Zuany-Amorim C, Sawicka E, Manlius C et al. Suppression of airway eosinophilia by killed *Mycobacterium vaccae*-induced allergen-specific regulatory T-cells. Nat Med 2002; 8:625–9.